Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-656 vs Kalydeco in Healthy Volunteers
NCT02599792Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deutivacaftor in cystic fibrosis (CF) (6 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 7 days and Area Under the Concentration Time Curve at 96 hours. Started Nov 2015; status: completed.
02
Drugs
deutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02599792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599792.